-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $2

Benzinga·11/24/2025 11:42:05
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $1.5 to $2.